CN108883106A - 使用了乐伐替尼和依维莫司的肾细胞癌治疗 - Google Patents

使用了乐伐替尼和依维莫司的肾细胞癌治疗 Download PDF

Info

Publication number
CN108883106A
CN108883106A CN201780020786.5A CN201780020786A CN108883106A CN 108883106 A CN108883106 A CN 108883106A CN 201780020786 A CN201780020786 A CN 201780020786A CN 108883106 A CN108883106 A CN 108883106A
Authority
CN
China
Prior art keywords
grades
dosage
insufferable
everolimus
laboratory abnormalities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780020786.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·克雷默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CN108883106A publication Critical patent/CN108883106A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780020786.5A 2016-04-15 2017-04-17 使用了乐伐替尼和依维莫司的肾细胞癌治疗 Pending CN108883106A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322916P 2016-04-15 2016-04-15
JP2016-081787 2016-04-15
JP2016081787 2016-04-15
US62/322,916 2016-04-15
PCT/JP2017/015461 WO2017179739A1 (fr) 2016-04-15 2017-04-17 Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus

Publications (1)

Publication Number Publication Date
CN108883106A true CN108883106A (zh) 2018-11-23

Family

ID=60041779

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780020786.5A Pending CN108883106A (zh) 2016-04-15 2017-04-17 使用了乐伐替尼和依维莫司的肾细胞癌治疗

Country Status (7)

Country Link
EP (1) EP3442532A4 (fr)
KR (1) KR20180129795A (fr)
CN (1) CN108883106A (fr)
AU (1) AU2017249459A1 (fr)
CA (1) CA3019682A1 (fr)
SG (1) SG11201808774RA (fr)
WO (1) WO2017179739A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4168016A2 (fr) * 2020-06-17 2023-04-26 Merck Sharp & Dohme LLC Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101337931A (zh) * 2003-12-25 2009-01-07 卫材R&D管理有限公司 喹啉羧酰胺的甲磺酸盐的醋酸合物的结晶(i)及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101337931A (zh) * 2003-12-25 2009-01-07 卫材R&D管理有限公司 喹啉羧酰胺的甲磺酸盐的醋酸合物的结晶(i)及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANA M. MOLINA等: "A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)", 《CANCER CHEMOTHER PHARMACOL》 *
ROBERT J MOTZER等: "Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial", 《LANCET ONCOL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用

Also Published As

Publication number Publication date
AU2017249459A1 (en) 2018-10-25
EP3442532A1 (fr) 2019-02-20
WO2017179739A1 (fr) 2017-10-19
SG11201808774RA (en) 2018-11-29
KR20180129795A (ko) 2018-12-05
CA3019682A1 (fr) 2017-10-19
EP3442532A4 (fr) 2019-12-11

Similar Documents

Publication Publication Date Title
Camilleri et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
US20200375975A1 (en) Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
BR112014027841B1 (pt) Uso de derivados de pirazola na fabricação de um fármaco para prevenir ou tratar constipação
Feitosa et al. II Guidelines for perioperative evaluation of the Brazilian Society of Cardiology
TW201410247A (zh) 醫藥組合
Kay et al. Idiopathic edema
US11834445B2 (en) Polymorphic forms of metopimazine
Hasler Approach to the patient with nausea and vomiting
Hansen et al. Glucagon-like peptide 2 inhibits postprandial gallbladder emptying in man: a randomized, double-blinded, crossover study
Pratama et al. Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: A systematic review
Gietka-Czernel et al. Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation—Tirosint SOL [Opinia ekspertów dotycząca stosowania płynnej postaci lewotyroksyny oraz nowego preparatu Tirosint SOL u chorych na niedoczynność tarczycy]
CN108883106A (zh) 使用了乐伐替尼和依维莫司的肾细胞癌治疗
Herrero-Beaumont et al. Use of crystalline glucosamine sulfate in osteoarthritis
US20220184006A1 (en) Combination therapy
AU2018287810A1 (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
JP2022514125A (ja) Ｆａｓ信号伝達抑制用ペプチドを含む肥満、脂肪肝又は脂肪肝炎の予防又は治療用薬学的組成物
US20220040168A1 (en) Treatment of hepatocellular carcinoma
CN103037901B (zh) 抑制cd36以控制肥胖和胰岛素敏感性
US20190142819A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
Eun et al. Pheochromocytoma with markedly abnormal liver function tests and severe leukocytosis
RU2785893C2 (ru) Лечение почечно-клеточной карциномы ленватинибом и эверолимусом
CN102631357B (zh) 一种缬沙坦与氢氯噻嗪药物组合物片剂及其制备方法
Kavanagh Antihypertensive drugs
Zhu Use of chemotherapy and traditional Chinese medicine for advanced cancers: A retrospective study of 68 patients (1993-2010).
Hajishafiee The effects of the amino acid, L-tryptophan, alone or with the fatty acid, lauric acid, on energy intake and postprandial glycaemia in health, obesity and type 2 diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123